Fitch projects 23 new drug filings for 2010

Looking at the new drug approval pace so far, Fitch Ratings estimates that drug authorities will field 23 new drug filings by the end of the year--the same slow pace seen over the past few years. The FDA has OK'd six new molecular entities and one vaccine while the European Medicines Agency authorized the marketing of five NMEs and two vaccines. Fitch also expects that licensing will be favored over consolidation deals in 2010. Release

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.